PREVUE-VALVE and the New Era of Cardiac Screening
.png)
The actual prevalence of valvular heart disease (VHD) among older Americans has long been underestimated. Previous research relied on cohorts of patients already referred for echocardiography, resulting in significant gaps. Until now, the true scope of the problem has remained elusive.
The PREVUE-VALVE trial, presented at TCT 2025 (San Francisco, CA), represents a transformative breakthrough. For the first time, researchers recruited a rigorously representative, unselected sample of adults aged 65–85 across all 50 states, using modern outreach through retail pharmacy databases (CVS and Walgreens), email, mail, and messaging. Over 3,000 participants received comprehensive at-home cardiac assessments, including ECG, echocardiography, blood sampling, and health-status review, which were analyzed by independent labs. The methodology ensured excellent representation of women (57.1%) and racial/ethnic minorities (14.8% Black, 9.4% Hispanic), making the findings uniquely generalizable and clinically relevant.
The results were striking: significant VHD (moderate or greater regurgitation/stenosis) affects 8.2% of older adults, rising to 14.7% in those aged 80–85. Tricuspid regurgitation was most common (3.7%), with aortic stenosis (3.1%), mitral regurgitation (2.0%), and aortic regurgitation (0.7%) following. Over 4.7 million older Americans have significant, often silent valve disease, and many remain entirely unaware of their condition. PREVUE-VALVE’s key message is clear: millions are at risk but unrecognized or undertreated, underscoring the urgent need for scalable, equitable screening and early intervention.
As a practicing cardiologist, this study validates the clinical imperative for advanced screening. AISAP’s FDA-approved, AI-augmented point-of-care ultrasound solution embodies this vision: designed for simplicity, accuracy, and access, AISAP can be used by novice, non-cardiologists at the bedside or in the community. By leveraging AI, our solution reliably identifies cardiac disease, including VHD, at the earliest stage, enabling prompt diagnosis and intervention. With billing support and proven ease of use, AISAP bridges the gap highlighted by PREVUE-VALVE, empowering clinicians and expanding access to life-saving screening for all.
AISAP stands ready to help change the trajectory of valvular disease—bringing precise, AI-driven screening to every corner of the healthcare system. Now, more than ever, it is time to act. Let us ensure that every patient at risk is recognized, treated, and given the best chance for heart health.
